Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Psoriasis Drugs Market - Expected to Reach $21.4 Billion by 2022 - Research and Markets

Research and Markets
Posted on: 27 Dec 17

The "Psoriasis Drugs Market 2016-2022" report has been added to Research and Markets' offering.

The global psoriasis drugs market is expected to be valued at $21.4 billion by 2022, as per a new report. The increasing number of reimbursement policies for treatment, advanced diagnostic tools, raised disease awareness and improved technological systems are likely to increase the adoption of therapeutics.

Additionally, the rising prevalence and incidence of psoriasis is anticipated to fuel the market growth. The condition has neither exact causes nor treatments to cure. Certain environmental and genetic factors may trigger the disease onset. Most treatments for the condition target to decelerate the severity of the disease by stopping the keratinocyte hyperproliferation. The disease symptoms can be managed by following a healthy lifestyle.

Further key findings from the report suggest:

  • Tumor Necrosis Factor-inhibitors dominated the psoriasis therapeutic market in 2016 owing to its higher usage by healthcare practitioners and easy availability.
  • TNF-inhibitors are likely to lose market shares over the forecast period due to increasing adoption of IL-inhibitor therapy over conventional TNF-inhibitors
  • Interleukin-inhibitors sector is expected to grow at lucrative CAGR of 19.4% over the forecast period because of improved safety and efficacy profiles of Interleukin-inhibiting drugs.
  • The U.S. market is the dominant region in the psoriasis therapeutic space. It led the market in terms of revenue with $4.4 billion in 2016 due to the increasing number of patients seeking treatment and presence of well-established healthcare services.

Companies Mentioned

  • AbbVie Inc.
  • Amgen, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Celgene Corporation

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Market Overview

Chapter 5 Product Pipeline

Chapter 6 Competitive Landscape

Chapter 7 Market Outlook

For more information about this report visit https://www.researchandmarkets.com/research/w7lqwn/psoriasis_drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20171227005436/en/

Business Wire
www.businesswire.com

Last updated on: 27/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.